Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog

Pharmacotherapy

Volumn 29, Issue 12 PART2, 2009, Pages

  Meece, Jerry ^a  

^a Plaza Pharmacy and Wellness Center ^*  (United States)

Author keywords

GLP 1 analogs; Incretins; Liraglutide; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; EXENDIN 4; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GRISEOFULVIN; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LISINOPRIL; LONG ACTING DRUG; METFORMIN; PARACETAMOL; PLACEBO; ROSIGLITAZONE;

ACUTE DRUG ADMINISTRATION; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CELL FUNCTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INSULIN RELEASE; KIDNEY DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHARMACODYNAMICS; REVIEW; SINGLE DRUG DOSE; STOMACH EMPTYING; VOMITING; WEIGHT REDUCTION;

AMINO ACID SEQUENCE; ANIMALS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MOLECULAR SEQUENCE DATA; TIME FACTORS;

EID: 73249118222     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.pt2.33S     Document Type: Review

References (76)

1. International Diabetes Federation. Diabetes atlas, 3rd ed. Brussels, Belgium: International Diabetes Federation, 2007. Available from http://www.eatlas.idf.org.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services, 2007.
3. National Institutes of Health. National diabetes statistics 2007-prevalence of diagnosed and undiagnosed diabetes in the United States, all ages, 2007. Available from http://diabetes. niddk.nih.gov/dm/pubs/statistics/ #allages. Accessed August 14, 2009.
4. Weir GC, Bonner-Weir S. Five stages of evolving β-cell dysfunction during progression to diabetes. Diabetes 2004;53(suppl 3):S16-21.
5. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218.
6. United Kingdom Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
7. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20:876-913.
8. Agerso H, Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 2003;19:141-50.
9. Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987;211:169-74.
10. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-4.
11. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.
12. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999;23:304-11.
13. Naslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol Regul Integr Comp Physiol 1999;277:R910-16.
14. Edvell A, Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology 1999;140:778-83.
15. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulindependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-32.
16. Rachman J, Barrow BA, Levy JC, Turner RC. Nearnormalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997;40:205-11.
17. Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004;53:654-62.
18. Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585-96.
19. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35.
20. Gutniak MK, Linde B, Holst JJ, Efendic S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 1994;17:1039-44.
21. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664-9.
22. Pridal L, Deacon CF, Kirk O, Christensen JV, Carr RD, Holst JJ. Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma. Eur J Drug Metab Pharmacokinet 1996;21:51-9.
23. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001;24:1416-21.
24. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagonlike peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003;26:791-8.
25. Holst JJ. The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes Obes Metab 2008;10:14-21.
26. Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 2009;5:199-211.
27. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202.
28. Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide [abstract]. Diabetes 2008;57:A164.
29. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998;41:271-8.
30. Bjornsdottir I, Olsen A, Larsen U, et al. Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptdyl peptidase IV and neutral endopeptidase [abstract]. Diabetologia 2008;51:S356.
31. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25:1398-404.
32. Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled doseescalation study. Int J Clin Pharmacol Ther 2008;46:273-9.
33. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol 2006;46:635-41.
34. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and - and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-94.
35. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002;51:424-9.
36. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide [published online ahead of print September 1, 2009]. Br J Clin Pharmacol. Available from http://dx.doi.org/10.1111/j.1365-2125.2009.03536.x.
37. Davidson JA, Falahati A, Brett J. Mild renal impairment has no effect on the efficacy and safety of liraglutide. Presented at the 18th annual meeting and clinical congress of the American Association of Clinical Endocrinologists, Houston, TX, May 13-17, 2009.
38. Flint A, Nazzal K, Jagielski P, Segel S, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide [abstract]. Diabetes 2007;56:A145.
39. Kapitza C, Flint A, Spitzer H, Hindsberger C, Zdravkovic M. The effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide [abstract]. Diabetes 2008;57:A593.
40. Rosenstock J, Gumprecht J, Szyprowska E, et al. Pharmacokinetics of liraglutide vs exenatide in type 2 diabetes: sustained vs fluctuating concentrations over 24 hours [abstract]. Diabetes 2009;58:A150.
41. Malm-Erjefalt M, Ekblom M, Brondsted L, Vouis J, Lennernas H, Zdravkovic M. A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects [abstract]. Diabetes 2008;57:A130.
42. Kapitza C, Flint A, Hindsberger C, Zdravkovic M. The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol [abstract]. Diabetes 2008;57:A593.
43. Jacobsen LV, Brondsted L, Vouis J, Zdravkovic M. A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug [abstract]. Diabetes 2008;57:A566.
44. Harder H, Nielsen L, Thi TD, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-21.
45. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the longacting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-42.
46. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a longacting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care 2007;30:1608-10.
47. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
48. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
49. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dosedependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;81:161-81.
50. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, paralleltreatment trial. Lancet 2008;373:473-81.
51. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced β cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998;95:2498-502.
52. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY. Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 2001;50:69-76.
53. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001;15:312-21.
54. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol 2000;143:717-25.
55. Nielsen JH, Galsgaard ED, Moldrup A, et al. Regulation of beta-cell mass by hormones and growth factors. Diabetes 2001;5(suppl 1):S25-9.
56. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-91.
57. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulinproducing cells. Endocrinology 2002;143:3152-61.
58. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4.
59. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human GLP-1 analogue liraglutide on beta-cell function in normal living conditions. Diabetes Care 2007;30:2032-3.
60. Garber A, Henry R, Ratner R, et al. Significantly better glycemic control and weight reduction with liraglutide, a oncedaily human GLP-1 analog, compared with glimepiride: all as monotherapy in type 2 diabetes [abstract]. Diabetes 2008;57:LB3.
61. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analog, added to sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes [abstract]. Diabetes 2008;57:A4.
62. Bregenholt S, Moldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem Biophys Res Commun 2005;330:577-84.
63. Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003;140:123-32.
64. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-5.
65. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999;42:856-64.
66. Friedrichsen BN, Neubauer N, Lee YC, et al. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006;188:481-92.
67. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjets with type 2 diabetes [abstract]. Diabet Med 2005;22:1023.
68. Horowitz M, Flint A, Doran S, et al. Effects of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetes [abstract]. Diabetologia 2008;51:S355.
69. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001;50:2530-9.
70. Raun K, von Voss P, Knudsen LB. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 2007;15:1710-16.
71. Zinman B, Gerich J, Buse J, et al. Effect of the GLP-1 analog liraglutide on glycemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial [abstract]. Diabetologia 2008;51:S359.
72. Colagiuri S, Frid A, Zdravkovic M, et al. Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes [abstract]. Diabetologia 2008;51:S360.
73. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-51.
74. Jendle J, Nauck MA, Matthews D, et al. Liraglutide, a oncedaily human GLP-1 analog, reduces fat percentage, visceral and subcutaneous adipose tissue and hepatic steatosis compared with glimepiride when added to metformin in subjects with type 2 diabetes [abstract]. Diabetes 2008;57:A32-3.
75. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008;48:592-8.
76. Bosi E, Byiers SR, Cohen SE. Vildagliptin significantly decreases blood pressure (BP) in hypertensive patients (pts) with type 2 diabetes (T2DM) compared with metformin [abstract]. Diabetes 2007;56:A139.